: GSK and Sanofi shares surge after Florida ruling dismisses Zantac lawsuits in what one analyst describes as ‘best-case scenario’

After a Florida judge threw out thousands of lawsuits involving heartburn drug Zantac on Tuesday, causing a number of pharmaceutical stocks to soar, analysts are bullish about forthcoming state cases.

Previous post Bond Report: Benchmark Treasury yields slightly softer amid recession concerns
Next post Peter Morici: The Fed should keep hiking rates, but talk about it less